Soligenix, Inc. (SNGX): Capital Expenditures
$5.9K
Year ended 2025-12-31
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $5.9K | n/a | 2026-03-31, From 2025-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Soligenix, Inc. (SNGX) | 2025-12-31 | $5.9K | n/a |
| Earth Science Tech, Inc. (ETST) | 2026-03-31 | $756.6K | +0.5% |
| Can-Fite BioPharma Ltd. (CANF) | 2025-12-31 | $2.0K | -60.0% |
| FibroBiologics, Inc. (FBLG) | 2025-12-31 | $262.0K | +42.4% |
| Nanoviricides, Inc. (NNVC) | 2025-06-30 | $57.0K | -63.6% |
| Cocrystal Pharma, Inc. (COCP) | 2025-12-31 | $12.0K | +50.0% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $112.0K | -18.8% |
| GRI Bio, Inc. (GRI) | 2025-12-31 | $3.0K | n/a |
| CNS Pharmaceuticals, Inc. (CNSP) | 2025-12-31 | $18.2K | +334.0% |
Compare SNGX, ETST, CANF, FBLG side by side · Screen every company in Pharmaceutical Preparations ↗